Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

According to Precedence Research, the radiopharmaceuticals market size has been estimated at USD 7.51 billion in 2025 and is projected to reach approximately USD 14.44 billion by 2034, growing at a ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Elevated circulating tumor DNA (ctDNA) fraction and tumor suppressor gene loss are associated with worse prognosis in patients with prostate cancer liver metastases (PCLM), according to investigators.

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

A new FDA approval has brought a renewed sense of hope as an innovative new treatment approach is now available to ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...